Boron‐10 carriers and their applications in boron neutron capture therapy
Precision Radiation Oncology · 2026-06 · 10 (2) · 205-241
DOI: 10.1002/pro6.70061 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Precision Radiation Oncology, online erschienen am 08.04.2026. Verfasst von Dachao Tang und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Petrochemical Engineering Changzhou University Changzhou China. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 227 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Boron neutron capture therapy (BNCT) has emerged as a promising therapeutic modality in cancer treatment, demonstrating the ability to selectively eliminate cancer cells through the 10 B(n,α) 7 Li nuclear reaction with minimal side effects on normal tissues. As a binary, target‐specific therapeutic modality for malignancies, BNCT critically depends on novel boron delivery carriers that exhibit high tumor affinity and prolonged intratumoral retention. Although several boron carriers have received Food and Drug Administration approval for clinical investigation, leading carriers such as L‐p‐boronophenylalanine (BPA) and sodium borocaptate (BSH) continue to require high infusion doses and exhibit limited tumor selectivity and affinity, short systemic half‐lives, and limited in vivo stability. These challenges have stimulated extensive global research into novel boron‐10 carriers and innovative carrier platforms, including amino acids, sugars, porphyrin derivatives, nucleotides, and a variety of nanocarrier systems. This review provides a systematic classification of high‐abundance boron‐10 carriers, critically examines radio‐boron research, and evaluates the potential integration of BNCT into clinical diagnostics and advanced cancer treatment protocols. By detailing the current status of novel boron‐10 carriers, this review further aims to elucidate critical challenges and opportunities in BNCT drug development, ultimately providing a theoretical foundation for next‐generation BNCT interventions.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Petrochemical Engineering Changzhou University Changzhou China.
- Guangdong Engineering Research Center of Boron Neutron Therapy and Application in Malignant Tumors The Tenth Affiliated Hospital Southern Medical University (Dongguan People's Hospital) Southern Medical University Dongg…
- Departments of Diagnostic Radiology Yong Loo Lin School of Medicine National University of Singapore Singapore Singapore.
- Cancer Center Dongguan Engineering Research Center for Innovative Boron Drugs and Novel Radioimmune Drugs The Tenth Affiliated Hospital Southern Medical University (Dongguan People's Hospital) Southern Medical Universit…
- School of Pharmacy China Pharmaceutical University Nanjing Jiangsu China.
ORCID-Profile: Mengqi Shi, Xiao Yan Zhao, Zhigang Liu, Xiao Xu
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Tang, D., Shi, M., Mao, Z., Chen, W., Li, X., Zhao, X. Y., Liu, Z., & Xu, X. (2026). Boron‐10 carriers and their applications in boron neutron capture therapy. Precision Radiation Oncology, 10(2), 205-241. https://doi.org/10.1002/pro6.70061
Vancouver
Tang D, Shi M, Mao Z, Chen W, Li X, Zhao XY, et al. Boron‐10 carriers and their applications in boron neutron capture therapy. Precision Radiation Oncology. 2026;10(2):205-241. doi:10.1002/pro6.70061
BibTeX
@article{Tang2026,
author = {Tang, Dachao and Shi, Mengqi and Mao, Zhichen and Chen, Weiya and Li, Xiaoling and Zhao, Xiao Yan and Liu, Zhigang and Xu, Xiao},
title = {Boron‐10 carriers and their applications in boron neutron capture therapy},
journal = {Precision Radiation Oncology},
year = {2026},
volume = {10},
number = {2},
pages = {205--241},
doi = {10.1002/pro6.70061}
}
EUVIMED